| Recruiting | Monotherapy vs Combination Therapy for Bone Infections Caused by Pseudomonas Aeruginosa NCT07056881 | Centre Hospitalier de Saint-Denis | — |
| Recruiting | Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa NCT06738771 | Centre Hospitalier Régional d'Orléans | — |
| Recruiting | Pathobiomes in Gut of Critically Ill Patients NCT06822465 | University of Chicago | — |
| Active Not Recruiting | PMT for MDRO Decolonization NCT05632315 | University of Pennsylvania | Phase 2 |
| Recruiting | A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF a NCT06016088 | Respirion Pharmaceuticals Pty Ltd | Phase 1 / Phase 2 |
| Completed | Pseudomonas Aeruginosa Infections Among COVID-19 Patients in Intensive Care Units at CHRU of Nancy (Pyo-COVID- NCT06141837 | Central Hospital, Nancy, France | — |
| Unknown | Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis NCT06035055 | Sunshine Coast Hospital and Health Service | Phase 4 |
| Completed | Animal-Assisted Visitation Program Chlorhexidine Trial NCT04171817 | Johns Hopkins Bloomberg School of Public Health | Phase 4 |
| Completed | Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibr NCT05616221 | Armata Pharmaceuticals, Inc. | Phase 2 |
| Unknown | Molecular Detection Of Efflux Pump and Virulence Factors Genes in Pseudomonas Aeruginosa NCT05642767 | Sohag University | — |
| Unknown | Clinical Outcomes in Patients With Infection by Resistant Microorganism NCT05880069 | Hospital Universitario Virgen Macarena | — |
| Completed | Carbapenem-resistant Pseudomonas Aeruginosa: the SAMPAN Study. NCT05282082 | Erasmus Medical Center | — |
| Terminated | Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections NCT05210387 | Hospital Moinhos de Vento | N/A |
| Completed | Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aerugi NCT04596319 | Armata Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Recruiting | Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies NCT04335383 | University Hospital, Grenoble | — |
| Unknown | Cross Transmissions of Pseudomonas Aeruginosa Between Children From a Same Cystic Fibrosis Center. NCT03910920 | Queen Fabiola Children's University Hospital | — |
| Completed | Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infectio NCT03638830 | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Phase 2 |
| Unknown | Role of Pseudomonas Aeruginosa Biofilms in Exacerbations in Patients With Bronchiectasis With and Without Chro NCT04803695 | Hospital Clinic of Barcelona | — |
| Terminated | Targeted AntiBiotics for Chronic Pulmonary Diseases NCT03262142 | Chronic Obstructive Pulmonary Disease Trial Network, Denmark | Phase 4 |
| Unknown | Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections NCT03510351 | Temple University | — |
| Completed | Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects NCT02696902 | MedImmune LLC | Phase 2 |
| Completed | Impact of the Contamination Mode on the Clinical Evolution During Pseudomonas Aeruginosa Ventilator Acquired P NCT01745796 | University Hospital, Grenoble | — |
| Completed | The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis NCT01616862 | Zafer Soultan | — |
| Completed | Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways NCT01404234 | Gilead Sciences | Phase 3 |
| Completed | A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapi NCT01319253 | Indiana University | — |
| Completed | Second Open Label Extension to Bridging Study CTBM100C2303 NCT01069705 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Sino-nasal Inhalation of Colistin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization NCT01035853 | University of Jena | Phase 2 |
| Completed | Open Label Extension to Bridging Study CTBM100C2303 NCT00982930 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Volatile Organic Compounds in Cystic Fibrosis NCT01379040 | Landon Pediatric Foundation | — |
| Completed | Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization NCT00774072 | University of Jena | Phase 2 |
| Completed | Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild L NCT00712166 | Gilead Sciences | Phase 3 |
| Completed | Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa NCT00691587 | Humanigen, Inc. | Phase 1 / Phase 2 |
| Completed | Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo NCT00515229 | University Hospital Tuebingen | Phase 2 |
| Completed | Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis NCT00633191 | Immunsystem AB | Phase 1 / Phase 2 |
| Completed | Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection NCT01055847 | Gilead Sciences | Phase 2 |
| Terminated | Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis NCT00333385 | Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche | Phase 4 |
| Approved For Marketing | Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis NCT00989807 | Gilead Sciences | — |